Galmed Pharmaceuticals Ltd 6-K, filed Sep 3, 2026
Galmed Pharmaceuticals Ltd. (EOCN)
About this 6-K
Galmed Pharmaceuticals Ltd filed this 6-K on September 3, 2026.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of September 2026
001-36345
(Commission File Number)
GALMED PHARMACEUTICALS LTD.
(Exact name of Registrant as specified in its charter)
c/o Meitar Law Offices Abba Hillel Silver Rd.,
Ramat Gan, 5250608
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On September 3, 2026, Galmed Pharmaceuticals Ltd. (the “Company”) held an Annual General Meeting of Shareholders (the “Meeting”). At the Meeting, the Company’s shareholders voted on all of the proposals described in the proxy statement for the Meeting included as an exhibit to the Company’s Report of Foreign Private Issuer on Form 6-K furnished by the Company to the Securities and Exchange Commission (the “SEC”) on July 22, 2026, as amended by the Amended Proxy Statement which was included as an exhibit to the Company’s report of Foreign Private Issuer on Form 6-K, furnished to the SEC on August 19, 2026. The proposals brought before the shareholders at the Meeting were approved by the shareholders of the Company with the requisite majority in accordance with the Israeli Companies Law, 5759-1999.
This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration Nos. 333-206292, 333-227441, 333-284163 and 333-290399) and the Company’s Registration Statement on Form F-3 (Registration Nos. 333-272722 and 333-283241).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Galmed Pharmaceuticals Ltd. | ||
| Date: September 3, 2026 | By: | /s/ Allen Baharaff |
| Allen Baharaff | ||
| President and Chief Executive Officer | ||